MADRIGAL PHARMACEUTICALS, INC. - 8-K Filing
Madrigal Pharmaceuticals reports Q3 2026 net revenues of $431.3 million and achieves first quarter of profitability with Rezdiffra sales growing 50% YoY. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $MDGL